Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 2/20 | 0.48 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.48 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 5/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9386993 | 0.89 | CYP2C19 (0.45) | PRMT1PRMT3CARM1PRMT6PRMT8 | |
| SCHEMBL1697723 | 0.84 | PRMT1 (0.65) | PRMT1PRMT3CARM1PRMT6PRMT8 | |
| SCHEMBL2750873 | 0.83 | PRMT3 (0.46) | PRMT1PRMT3CARM1PRMT6PRMT8 | |
| SCHEMBL15189352 | 0.82 | PRMT1 (0.50) | PRMT1PRMT3CARM1PRMT6PRMT8 | |
| SCHEMBL12866023 | 0.82 | TSHR (0.43) | SIGMAR1CYP2C19MEN1GLAKMT2A | |
| SCHEMBL17287873 | 0.82 | PRMT3 (0.43) | PRMT1PRMT3CARM1PRMT6PRMT8 | |
| SCHEMBL27462008 | 0.81 | CYP2C19 (0.46) | PRMT1PRMT3CARM1PRMT6PRMT8 | |
| SCHEMBL7179758 | 0.81 | PRMT1 (0.61) | PRMT1PRMT3CARM1PRMT6PRMT8 | |
| SCHEMBL28932451 | 0.80 | CYP2C19 (0.38) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL8503680 | 0.80 | PRMT1 (0.70) | PRMT1PRMT3CARM1PRMT6PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3267794-B1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | UNIV YALE (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3201168-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LTD (IN) | 2020-03-18 | — | — | EP | disclosed |
| WO-2020026054-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | CELLIX BIO PRIVATE LIMITED (IN) | 2020-02-06 | — | — | WO | disclosed |
| WO-2019243970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES AND CANCER | CELLIX BIO PRIVATE LIMITED (IN) | 2019-12-26 | — | — | WO | disclosed |
| WO-2018029545-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2018-02-15 | — | — | WO | disclosed |
| WO-2017068477-A1 | COMPOUND, COMPOSITION AND USES THEREOF | RAO M SURYA (IN) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017037566-A1 | COMPOUND, COMPOSITION AND USES THEREOF | RAO M SURYA (IN) | 2017-03-09 | — | — | WO | disclosed |
| US-9573927-B2 | Compositions and methods for the treatment of severe pain | CELLIX BIO PRIVATE LIMITED (IN) | 2017-02-21 | — | — | US | disclosed |
| US-9499527-B2 | Compositions and methods for the treatment of familial amyloid polyneuropathy | CELLIX BIO PRIVATE LIMITED (IN) | 2016-11-22 | — | — | US | disclosed |
| US-9403857-B2 | Compositions and methods for the treatment of metabolic syndrome | CELLIX BIO PRIVATE LIMITED (IN) | 2016-08-02 | — | — | US | disclosed |
| US-20150291590-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISEASES | CELLIX BIO PRIVATE LTD (IN) | 2015-10-15 | — | — | US | disclosed |
| US-20150152081-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEVERE PAIN | CELLIX BIO PRIVATE LIMITED (IN) | 2015-06-04 | — | — | US | disclosed |
| US-20150141384-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS | KANDULA MAHESH (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141479-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MODERATE TO SEVERE PAIN | CELLIX BIO PRIVATE LIMITED (IN) | 2015-05-21 | — | — | US | disclosed |
| US-20150126593-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ASTHMA AND ALLERGY | CELLIX BIO PRIVATE LIMITED (IN) | 2015-05-07 | — | — | US | disclosed |
| US-20150080345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2015-03-19 | — | — | US | disclosed |
| US-5914072-A | DISPERSANTS FOR SOLIDS; FOR USE IN PAINTS, INKS | BASF AKTIENGESELLSCHAFT (DE) | 1999-06-22 | — | — | US | disclosed |
| US-5863879-A | POLYMER IS FORMED BY REACTING A POLYMER CONTAINING VINYLAMINE UNIT WITH COMPOUNDS CONTAINING ALDEHYDE OR KETO GROUPS AND OPTIONAL OTHER AMINE OR ALOCHOL CONTAINING COMPOUNDS SUCH AS AMINAL, HEMIAMINAL OR AMINAL ACETATE | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-26 | — | — | US | disclosed |
| EP-0756618-B1 | DYE-TRANSFER INHIBITORS FOR DETERGENTS | BASF AG (DE) | 1998-08-12 | — | — | EP | disclosed |
| EP-0759440-A2 | Phosphoric acid esters | BASF AKTIENGESELLSCHAFT (DE) | 1997-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291590-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISEASES | KYNU, TKT, SLC5A1 | PRMT1 1594/4885PRMT3 1523/4885CARM1 2863/4885 |
| US-20150126593-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ASTHMA AND ALLERGY | LTA4H, LTC4S, ALOX5 | PRMT1 2869/4885PRMT3 2954/4885CARM1 4166/4885 |
| US-20150080345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | FABP4, GYS2, FABP2 | PRMT1 3884/4885PRMT3 3937/4885CARM1 4415/4885 |
| US-20150141479-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MODERATE TO SEVERE PAIN | TARDBP, GLS2, CACNA1S | PRMT1 3094/4885PRMT3 3405/4885CARM1 4072/4885 |
| US-20150152081-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEVERE PAIN | CACNA1S, TARDBP, SCN1A | PRMT1 2834/4885PRMT3 3106/4885CARM1 3398/4885 |
| US-20150141384-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS | HTT, SNCA, PARK7 | PRMT1 3498/4885PRMT3 3535/4885CARM1 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.